MetaCap

Apnimed (APMD) vs Design Therapeutics (DSGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.

Summary

Apnimed is the larger company by market cap ($751.0 million vs $731.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APMD-27.84%DSGN-4.02%
+34%+2%-31%
Jul 31, 20261 yearOct 7, 2026
APMD-27.84%DSGN-4.02%
+30%-0%-31%
Jul 27, 20265 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APMD versus DSGN key metrics
MetricAPMDDSGN
Share price$18.04$11.69
Market cap$751.02M$731.58M
1-day change-3.27%-2.34%
YTD return—+24.63%
1-year return—+80.12%
5-year return—-17.96%
P/E ratio (TTM)2.50—
EPS (TTM)$7.22$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$35.29$17.25
52-week low$16.12$5.28
Distance from 52-week high-48.88%-32.23%
Average volume558.59K614.39K
Shares outstanding41.63M62.58M
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

APMD vs DSGN FAQ

Which is bigger, Apnimed or Design Therapeutics?

Apnimed (APMD) is larger, with a market capitalization of $751.02M compared with $731.58M for Design Therapeutics (DSGN).

Are Apnimed and Design Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons